Nahdi Medical Company
Symbool: 4164.SR
SAU
131.4
SARMarktprijs vandaag
19.3844
Koers/Winst Verhouding
6.6084
Koers/Winst Groei Verhouding
17.08B
MRK Kapitalisatie
- 0.04%
DIV Rendement
Nahdi Medical Company (4164-SR) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3481.84 | 909.7 | 1076.3 | 401 | |||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.net-receivables | 1024.06 | 433.5 | 130.2 | 140.3 | |||||
balance-sheet.row.inventory | 5902.14 | 1409.4 | 1182.8 | 1116.5 | |||||
balance-sheet.row.other-current-assets | 773.1 | 6.2 | 174.3 | 141.6 | |||||
balance-sheet.row.total-current-assets | 11181.15 | 2758.7 | 2563.6 | 1799.4 | |||||
balance-sheet.row.property-plant-equipment-net | 8990.01 | 2307.1 | 2080.4 | 2213.3 | |||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.intangible-assets | 200.6 | 51.2 | 47.1 | 44.2 | |||||
balance-sheet.row.goodwill-and-intangible-assets | 200.6 | 51.2 | 47.1 | 44.2 | |||||
balance-sheet.row.long-term-investments | 1017.72 | 254.3 | 253.8 | 230.1 | |||||
balance-sheet.row.tax-assets | -1017.72 | -254.3 | -253.8 | -230.1 | |||||
balance-sheet.row.other-non-current-assets | 1017.72 | 254.3 | 253.8 | 230.1 | |||||
balance-sheet.row.total-non-current-assets | 10208.32 | 2612.6 | 2381.3 | 2487.5 | |||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.total-assets | 21389.47 | 5371.3 | 4944.9 | 4286.9 | |||||
balance-sheet.row.account-payables | 4061.42 | 894.3 | 637.2 | 484 | |||||
balance-sheet.row.short-term-debt | 1357 | 304.2 | 375.9 | 367.4 | |||||
balance-sheet.row.tax-payables | 425.55 | 112.5 | 106.5 | 5.2 | |||||
balance-sheet.row.long-term-debt-total | 3211.87 | 870.6 | 792.2 | 991.6 | |||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||
balance-sheet.row.other-current-liab | 1189.38 | 26.8 | 156.4 | 126.1 | |||||
balance-sheet.row.total-non-current-liabilities | 4820.61 | 1277.5 | 1193.1 | 1397.5 | |||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.capital-lease-obligations | 4202.88 | 1174.8 | 1168.1 | 1359.1 | |||||
balance-sheet.row.total-liab | 11956.16 | 2908.6 | 2701.5 | 2683.3 | |||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.common-stock | 5200 | 1300 | 1300 | 1300 | |||||
balance-sheet.row.retained-earnings | 2935.94 | 794.4 | 663.8 | 112.6 | |||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1297.37 | 368.4 | 279.6 | 191 | |||||
balance-sheet.row.other-total-stockholders-equity | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.total-stockholders-equity | 9433.31 | 2462.8 | 2243.4 | 1603.6 | |||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 21389.47 | 5371.3 | 4944.9 | 4286.9 | |||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||
balance-sheet.row.total-equity | 9433.31 | 2462.8 | 2243.4 | 1603.6 | |||||
balance-sheet.row.total-liabilities-and-total-equity | 21389.47 | - | - | - | |||||
Total Investments | 1017.72 | 254.3 | 253.8 | 230.1 | |||||
balance-sheet.row.total-debt | 4568.87 | 1174.8 | 1168.1 | 1359.1 | |||||
balance-sheet.row.net-debt | 1087.02 | 265.1 | 91.8 | 958 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 914.85 | 944.2 | 937.9 | 857.3 | |||||
cash-flows.row.depreciation-and-amortization | 622.73 | 618.1 | 596.6 | 571.5 | |||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||
cash-flows.row.change-in-working-capital | -276.14 | -155 | 52.5 | -13.4 | |||||
cash-flows.row.account-receivables | -67.79 | -38.2 | 6.9 | -47.7 | |||||
cash-flows.row.inventory | -362.81 | -214.6 | -127 | 85.9 | |||||
cash-flows.row.account-payables | 279.57 | 257.1 | 153.2 | 43.7 | |||||
cash-flows.row.other-working-capital | -125.11 | -159.4 | 19.4 | -95.3 | |||||
cash-flows.row.other-non-cash-items | 171.08 | -38.6 | 80.8 | -81.4 | |||||
cash-flows.row.net-cash-provided-by-operating-activities | 1218.44 | 0 | 0 | 0 | |||||
cash-flows.row.investments-in-property-plant-an-equipment | -409.99 | -384.5 | -275.2 | -306.5 | |||||
cash-flows.row.acquisitions-net | 0.51 | 0.3 | 0.1 | 7.1 | |||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||
cash-flows.row.other-investing-activites | -33.11 | 0 | 0 | 0 | |||||
cash-flows.row.net-cash-used-for-investing-activites | -409.48 | -384.3 | -275.1 | -299.4 | |||||
cash-flows.row.debt-repayment | -449.56 | -435.7 | 0 | 0 | |||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||
cash-flows.row.dividends-paid | -713.89 | -715 | -300.3 | -1260 | |||||
cash-flows.row.other-financing-activites | -726.09 | -435.7 | -417 | -382.1 | |||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1553.45 | -1150.7 | -717.3 | -1642.1 | |||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.07 | -0.4 | -0.2 | 0 | |||||
cash-flows.row.net-change-in-cash | -744.55 | -166.6 | 675.3 | -607.5 | |||||
cash-flows.row.cash-at-end-of-period | 3481.84 | 909.7 | 1076.3 | 401 | |||||
cash-flows.row.cash-at-beginning-of-period | 4226.4 | 1076.3 | 401 | 1008.5 | |||||
cash-flows.row.operating-cash-flow | 1218.44 | 1368.7 | 1667.9 | 1334 | |||||
cash-flows.row.capital-expenditure | -409.99 | -384.5 | -275.2 | -306.5 | |||||
cash-flows.row.free-cash-flow | 808.45 | 984.2 | 1392.6 | 1027.5 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 8866.13 | 8713.7 | 8616.2 | 8066.2 | |||||
income-statement-row.row.cost-of-revenue | 5376.16 | 5191.5 | 5095.3 | 4761.5 | |||||
income-statement-row.row.gross-profit | 3489.97 | 3522.2 | 3520.9 | 3304.7 | |||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||
income-statement-row.row.research-development | 0 | - | - | - | |||||
income-statement-row.row.selling-general-administrative | 67.81 | - | - | - | |||||
income-statement-row.row.selling-and-marketing-expenses | 403.05 | - | - | - | |||||
income-statement-row.row.other-expenses | 12.43 | -2561.2 | 4.5 | 10 | |||||
income-statement-row.row.operating-expenses | 2583.36 | 2561.2 | 2535 | 2430.5 | |||||
income-statement-row.row.cost-and-expenses | 7256.73 | 7752.7 | 7630.2 | 7192 | |||||
income-statement-row.row.interest-income | 60.39 | 56.8 | 12.1 | 3 | |||||
income-statement-row.row.interest-expense | 57.8 | 50.5 | 79.4 | 78.9 | |||||
income-statement-row.row.selling-and-marketing-expenses | 403.05 | - | - | - | |||||
income-statement-row.row.total-other-income-expensenet | -867.76 | -961 | -64.7 | -62.3 | |||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||
income-statement-row.row.other-operating-expenses | 12.43 | -2561.2 | 4.5 | 10 | |||||
income-statement-row.row.total-operating-expenses | -867.76 | -961 | -64.7 | -62.3 | |||||
income-statement-row.row.interest-expense | 57.8 | 50.5 | 79.4 | 78.9 | |||||
income-statement-row.row.depreciation-and-amortization | 622.73 | 618.1 | 596.6 | 571.5 | |||||
income-statement-row.row.ebitda-caps | 1550.14 | - | - | - | |||||
income-statement-row.row.operating-income | 1609.4 | 961 | 1002.6 | 919.6 | |||||
income-statement-row.row.income-before-tax | 924.24 | 944.2 | 937.9 | 857.3 | |||||
income-statement-row.row.income-tax-expense | 43.02 | 51.6 | 50.1 | 44.7 | |||||
income-statement-row.row.net-income | 881.22 | 892.6 | 887.8 | 812.5 |
Vaak gestelde vragen
Wat is Nahdi Medical Company (4164.SR) totale activa?
Nahdi Medical Company (4164.SR) totale activa is 5371327292.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 4471747442.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.394.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.099.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.182.
Wat is Nahdi Medical Company (4164.SR) nettowinst (netto-inkomen)?
De nettowinst is 892618140.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1174755729.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 2561200000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 769939655.000.